Table of contents
Volume 86, Issue 4
Published online 12 February 2002 (499-663)
Review |
Clinical |
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics |
Letters to the Editor |
Book Review
Editorial
NICE verdict on Temozolomide: where next? FREE
M Brada
Br J Cancer 86: 499-500; doi:10.1038/sj.bjc.6600134
Review
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma FREE
J Dinnes, C Cave, S Huang and R Milne
Br J Cancer 86: 501-505; doi:10.1038/sj.bjc.6600135
Clinical
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET FREE
C Bokemeyer, C Kollmannsberger, K Oechsle, B M Dohmen, A Pfannenberg, C D Claussen, R Bares and L Kanz
Br J Cancer 86: 506-511; doi:10.1038/sj.bjc.6600122
FDG–PET. A possible prognostic factor in head and neck cancer FREE
W Halfpenny, S F Hain, L Biassoni, M N Maisey, J A Sherman and M McGurk
Br J Cancer 86: 512-516; doi:10.1038/sj.bjc.6600114
Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation FREE
H K Awwad, M Lotayef, T Shouman, A C Begg, G Wilson, S M Bentzen, H Abd El-Moneim and S Eissa
Br J Cancer 86: 517-523; doi:10.1038/sj.bjc.6600119
CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours FREE
T J Vogl, K Engelmann, M G Mack, R Straub, S Zangos, K Eichler, K Hochmuth and E Orenberg
Br J Cancer 86: 524-529; doi:10.1038/sj.bjc.6600116
Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer FREE
H Date, K Kiura, H Ueoka, M Tabata, M Aoe, A Andou, T Shibayama and N Shimizu
Br J Cancer 86: 530-533; doi:10.1038/sj.bjc.6600117
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours FREE
B C Goh, E E Vokes, A Joshi and M J Ratain
Br J Cancer 86: 534-539; doi:10.1038/sj.bjc.6600123
Molecular and Cellular Pathology
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients FREE
G Pérez-Tenorio and O Stål and members of the Southeast Sweden Breast Cancer Group
Br J Cancer 86: 540-545; doi:10.1038/sj.bjc.6600126
Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression FREE
B J Coventry, P-L Lee, D Gibbs and D N J Hart
Br J Cancer 86: 546-551; doi:10.1038/sj.bjc.6600132
Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma FREE
H Shimada, T Hoshino, S Okazumi, H Matsubara, Y Funami, Y Nabeya, H Hayashi, A Takeda, T Shiratori, T Uno, H Ito and T Ochiai
Br J Cancer 86: 552-557; doi:10.1038/sj.bjc.6600129
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma FREE
G Fontanini, P Faviana, M Lucchi, L Boldrini, A Mussi, T Camacci, M A Mariani, C A Angeletti, F Basolo and R Pingitore
Br J Cancer 86: 558-563; doi:10.1038/sj.bjc.6600130
Hypermethylation of the hMLH1 gene promoter in solitary and multiple gastric cancers with microsatellite instability FREE
K Sakata, G Tamura, Y Endoh, K Ohmura, S Ogata and T Motoyama
Br J Cancer 86: 564-567; doi:10.1038/sj.bjc.6600076
c-erbB-2 is not a major factor in the development of colorectal cancer FREE
J A McKay, J F Loane, V G Ross, M-M Ameyaw, G I Murray, J Cassidy and H L McLeod
Br J Cancer 86: 568-573; doi:10.1038/sj.bjc.6600127
Genetics and Genomics
Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer FREE
G Deng, E Peng, J Gum, J Terdiman, M Sleisenger and Y S Kim
Br J Cancer 86: 574-579; doi:10.1038/sj.bjc.6600148
Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays FREE
I Bièche, M Olivi, C Noguès, M Vidaud and R Lidereau
Br J Cancer 86: 580-586; doi:10.1038/sj.bjc.6600109
Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas FREE
N Shinoura, S Sakurai, F Shibasaki, A Asai, T Kirino and H Hamada
Br J Cancer 86: 587-595; doi:10.1038/sj.bjc.6600061
Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours FREE
F Abel, R-M Sjöberg, K Ejeskär, C Krona and T Martinsson
Br J Cancer 86: 596-604; doi:10.1038/sj.bjc.6600111
Experimental Therapeutics
Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity FREE
J Van heusden, R Van Ginckel, H Bruwiere, P Moelans, B Janssen, W Floren, B J van der Leede, J van Dun, G Sanz, M Venet, L Dillen, C Van Hove, G Willemsens, M Janicot and W Wouters
Br J Cancer 86: 605-611; doi:10.1038/sj.bjc.6600056
Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor FREE
C Bing, S T Russell, E E Beckett, P Collins, S Taylor, R Barraclough, M J Tisdale and G Williams
Br J Cancer 86: 612-618; doi:10.1038/sj.bjc.6600101
Variation in mitochondrial function in hypoxia-sensitive and hypoxia-tolerant human glioma cells FREE
M L Turcotte, M Parliament, A Franko and J Allalunis-Turner
Br J Cancer 86: 619-624; doi:10.1038/sj.bjc.6600087
A cyclin-dependent kinase inhibitor (p21WAF1/CIP1) affects thymidine incorporation in human liver cancer cells FREE
Y Gong, S Deng, M Zhang, G Wang, G Y Minuk and F Burczynski
Br J Cancer 86: 625-629; doi:10.1038/sj.bjc.6600099
Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation FREE
F Caballero, E Gerez, A Batlle and E Vazquez
Br J Cancer 86: 630-635; doi:10.1038/sj.bjc.6600102
Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y2-receptors FREE
K Maaser, M Höpfner, H Kap, A P Sutter, B Barthel, B von Lampe, M Zeitz and H Scherübl
Br J Cancer 86: 636-644; doi:10.1038/sj.bjc.6600100
Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1 FREE
S Tian, A J Hayes, L J Metheny-Barlow and L-Y Li
Br J Cancer 86: 645-651; doi:10.1038/sj.bjc.6600082
Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy FREE
L Prasmickaite, A Høgset, P K Selbo, B Ø Engesæter, M Hellum and K Berg
Br J Cancer 86: 652-657; doi:10.1038/sj.bjc.6600138
Letters to the Editor
Endothelial hyperplasia: an important indicator of actual angiogenesis FREE
J T Beranek
Br J Cancer 86: 658; doi:10.1038/sj.bjc.6600055
99mTc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours FREE
P Laverman, O C Boerman, G Storm and W J G Oyen
Br J Cancer 86: 659-660; doi:10.1038/sj.bjc.6600093
Reply: 99mTc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours FREE
M I Koukourakis
Br J Cancer 86: 660-661; doi:10.1038/sj.bjc.6600094
Book Review
Principles and practice of the biologic therapy of cancer (third edition) FREE
R T D Oliver
Br J Cancer 86: 662-663; doi:10.1038/sj.bjc.6600090
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
